Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files Form 6-K current reports under the Securities Exchange Act of 1934, along with registration statements on Form F-3 and Form S-8 referenced in those reports. These filings document key events in the company’s development as a commercial-stage medical device and diagnostics business focused on respiratory support and blood monitoring.
Recent Form 6-K reports describe transactions such as a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement that together outline Inspira’s equity financing tools. Other 6-Ks incorporate press releases on clinical and regulatory milestones, including progress with the HYLA non-invasive blood sensor, regulatory steps for the INSPIRA ART100 system in the United Arab Emirates, and financial results and business updates. Filings also cover shareholder meeting materials, board and executive changes, and adjustments to sales agreements for ordinary shares.
Through this page, users can review Inspira’s SEC-reported information on capital structure, financing arrangements, and material operational updates. Stock Titan’s tools can surface new 6-K submissions in real time and help summarize their contents, allowing readers to quickly understand how each filing relates to topics such as product commercialization, clinical studies, or corporate governance. For deeper analysis, investors can examine attachments referenced in the 6-Ks, including financial statements, management’s discussion and analysis, and opinions related to securities offerings.
Inspira Technologies Oxy B.H.N. Ltd. reports two key updates. First, it amended its senior convertible debenture with Bio-View Ltd., extending the deadline to satisfy certain prerequisites from 45 to 75 days and revising the required $5,000,000 investment so it must come from investors introduced under a placement agreement with A.G.P/ Alliance Global Partners.
Second, Inspira received a Nasdaq notice that it is not meeting the minimum market value of publicly held shares requirement of $35,000,000. The company has 180 days, until August 18, 2026, for its market value of publicly held shares to reach at least $35,000,000 for 10 consecutive business days, or its securities may face delisting unless a Nasdaq hearings panel grants relief.
Inspira Technologies is expanding its U.S. presence by deploying its FDA-cleared INSPIRA™ ART100 system at a new premier New York academic medical center ranked among the state’s top 10 hospitals. The system is being integrated into the hospital’s clinical workflow for a structured commercial evaluation.
The evaluation aims to define clinical protocols and assess potential broader institutional adoption, adding to existing commercial activity at other leading U.S. healthcare facilities. Inspira positions the ART100 as a foundation for its next-generation ART500 awake-oxygenation system and is also advancing its HYLA™ continuous blood monitoring platform.
Inspira Technologies Oxy B.H.N. Ltd. entered into a sales agreement allowing at-the-market offerings of its ordinary shares with an aggregate offering price of
The shares are issued under existing Form F-3 registrations and a new prospectus supplement. Inspira plans to use any net proceeds for general corporate purposes, including research and development, regulatory processes, marketing, and commercialization. The company is not obligated to sell any shares, and the sales agent will receive a
Inspira Technologies Oxy B.H.N. Ltd. is offering up to $2,015,985 of ordinary shares through an at-the-market program with A.G.P./Alliance Global Partners under its existing $75 million shelf registration.
The ATM facility lets the company sell shares on Nasdaq from time to time at prevailing prices, paying A.G.P. a 3% commission. Shares outstanding were 43,271,837 as of February 17, 2026, and would rise to 46,694,562 if the full amount were sold at $0.589 per share. The company plans to use net proceeds for research and development, regulatory work, commercialization and general corporate purposes.
The filing highlights substantial dilution for new investors, Nasdaq non-compliance with the $1.00 minimum bid price rule, and an auditor’s going concern paragraph, underscoring financing and listing risks alongside the capital raise.
Inspira Technologies OXY B.H.N. Ltd investor Joe Ronen Hayon has reported his ownership stake in the company. He beneficially owns 3,204,010 ordinary shares, representing 7.3% of the class as of December 31, 2025, based on 43,859,838 shares outstanding.
The holding consists of 655,623 ordinary shares, 2,491,228 ordinary shares from vested restricted stock units, and 57,159 ordinary shares issuable upon options exercisable within 60 days of December 31, 2025. He has sole voting and dispositive power over all 3,204,010 shares and no shared power or group relationships are reported.
Joe Ronen Hayon filed an amended Schedule 13G reporting beneficial ownership of 3,204,010 ordinary shares of Inspira Technologies OXY B.H.N. Ltd, representing 7.3% of the class as of December 31, 2025, based on 43,859,838 outstanding ordinary shares.
The holding consists of 655,623 ordinary shares, 2,491,228 ordinary shares vested from restricted stock units, and 57,159 ordinary shares issuable upon option exercise within 60 days of December 31, 2025. Hayon reports sole voting and dispositive power over all 3,204,010 shares and no shared power.
Inspira Technologies Oxy B.H.N. Ltd. received a Nasdaq notice on February 9, 2026 that its ordinary shares are not in compliance with the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days.
The notice has no immediate effect on trading, and the shares continue on the Nasdaq Capital Market under symbol IINN. The company has 180 days, until August 10, 2026, for its closing bid price to reach at least $1.00 for ten consecutive business days to regain compliance, with the possibility of a second 180‑day period if additional conditions are met.
If compliance is not restored within the allowed period, Nasdaq may delist the shares. Inspira plans to monitor its share price and consider available options, potentially including a reverse share split, to address the deficiency.
Inspira Technologies Oxy B.H.N. Ltd. reports a major commercial step: its FDA-cleared INSPIRA ART100 system has received official vendor approval from Clalit Health Services, described as the world’s second-largest integrated HMO with $12 billion in revenue.
This approval allows immediate procurement and operational use of the ART100 for cardiopulmonary procedures across Clalit’s network of medical centers, subject to its supply-chain protocols. Management frames this as a “definitive commercial inflection point” that may support long-term, high-quality revenue and provide a strong reference site as the company pursues commercialization in the U.S. and other markets.
The ART100 is cleared in the U.S. for cardiopulmonary bypass and for ECMO procedures outside the U.S., and serves as the platform for the in-development ART500 system. The company is also advancing its HYLA blood sensor platform, positioning itself within the life-support and MedTech space.
Inspira Technologies Oxy B.H.N. Ltd. entered a definitive agreement with a single institutional investor for a registered direct offering and concurrent private placement expected to raise approximately $4.75 million before fees. The company will sell 4,000,000 ordinary shares at $0.70 per share and pre-funded warrants for up to 2,785,715 shares at $0.6999 each, plus ordinary warrants to purchase up to 6,785,715 shares at $0.70 in a private placement.
The pre-funded warrants are exercisable immediately at $0.0001 per share, while the ordinary warrants become exercisable six months after issuance and expire five years after first exercise. Inspira also agreed to reduce the exercise price of 3,031,250 existing warrants from $1.28 to $0.70 and extend their expiration to February 5, 2031. Net proceeds are intended for working capital and general corporate purposes.
Inspira Technologies Oxy B.H.N. Ltd. is registering 6,785,715 ordinary share equivalents through a direct offering of 4,000,000 ordinary shares and pre-funded warrants to purchase up to 2,785,715 additional shares at combined prices around $0.70 per paired security and warrant.
In a concurrent private placement, the same investor will receive unregistered warrants to purchase up to 6,785,715 ordinary shares at an exercise price of $0.70, exercisable six months after issuance for five and a half years. The transaction is expected to generate gross proceeds of $4,749,721 and approximately $4.3 million in net proceeds, which the company plans to use for working capital and general corporate purposes.
Ordinary shares outstanding are expected to increase from 37,074,123 to 43,859,838 assuming full exercise of the pre-funded warrants, resulting in meaningful dilution for existing shareholders. The company also agreed to reduce the exercise price and extend the term of 3,031,250 existing warrants, further expanding potential future share issuance.